GlassScriptPhysician profile
James M Orsini
NPI 1922084185
$38,260.54
in general payments reported to CMS, 2019-2025
49 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,366 · 2021: $18K · 2022: $4,601 · 2023: $606 · 2024: $607 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.96 |
| Education | $268.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $24,989.67 | 2019-2022 | |
| Astellas Pharma US INC | $9,549.18 | 2019-2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $478.56 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Incyte Corporation | $365.63 | 2020-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $273.00 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $208.52 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Daiichi Sankyo INC. | $172.00 | 2019-2025 | Enhertu, Injectafer |
| Amgen INC. | $154.93 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.65 | 2019-2025 | |
| Genentech USA, INC. | $135.78 | 2019-2025 | Itovebi |
| Glaxosmithkline, LLC. | $132.12 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $124.80 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $120.23 | 2020-2025 | Xpovio |
| Gilead Sciences, INC. | $109.17 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $102.18 | 2021-2024 | Brukinsa |
Show all 47 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Orsini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.